REAGILA Drug Insight and Market Forecast - 2032

REAGILA Drug Insight and Market Forecast − 2032

“REAGILA Drug Insight and Market Forecast – 2032” report provides comprehensive insights about REAGILA for schizophrenia in the seven major markets. A detailed picture of the REAGILA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the REAGILA for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REAGILA market forecast analysis for schizophrenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

VRAYLAR/REAGILA (cariprazine) is an atypical antipsychotic used in the treatment of schizophrenia and manic or mixed episodes of bipolar disorder. The drug acts as a D2 and D3 receptor partial agonist, with high selectivity toward the D3 receptor. This mechanism is relatively unique since many other antipsychotics are D2 and 5-HT2A agonists. Action on the dopaminergic systems makes it also potentially useful as add-on therapy for major depressive disorder.

In September 2015, the FDA approved the drug, and was indicated in the treatment of schizophrenia and bipolar disorder. VRAYLAR is also sold under the brand name REAGILA in Europe. VRAYLAR was discovered and co-developed by Gedeon Richter and is licensed by Allergan, in the US and Canada.

Dosage and administration

The recommended dosage range is 1.5–6 mg once daily. The starting dosage is 1.5 mg daily and can be increased to 3 mg on the second day. Depending upon clinical response and tolerability, further dose adjustments can be made in 1.5 mg or 3 mg increments. The maximum recommended dosage is 6 mg daily. In short-term controlled trials, dosages above 6 mg daily do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions.

Mechanism of action

Cariprazine is a dopamine D3 and D2 receptor partial agonist with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the REAGILA description, mechanism of action, dosage and administration, research and development activities in schizophrenia.

Elaborated details on REAGILA regulatory milestones and other development activities have been provided in this report.

The report also highlights the REAGILA research and development activities in schizophrenia across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around REAGILA.

The report contains forecasted sales of for schizophrenia till 2032.

Comprehensive coverage of the late-stage emerging therapies for schizophrenia.

The report also features the SWOT analysis with analyst views for REAGILA in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REAGILA Analytical Perspective by DelveInsight

In-depth REAGILA Market Assessment

This report provides a detailed market assessment of REAGILA for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

REAGILA Clinical Assessment

The report provides the clinical trials information of REAGILA for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REAGILA dominance.

Other emerging products for schizophrenia are expected to give tough market competition to REAGILA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REAGILA in schizophrenia.

Our in-depth analysis of the forecasted sales data of REAGILA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REAGILA in schizophrenia.

Key Questions

What is the product type, route of administration and mechanism of action of REAGILA?

What is the clinical trial status of the study related to REAGILA in schizophrenia and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REAGILA development?

What are the key designations that have been granted to REAGILA for schizophrenia?

What is the forecasted market scenario of REAGILA for schizophrenia?

What are the forecasted sales of REAGILA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to REAGILA for schizophrenia?

Which are the late-stage emerging therapies under development for the treatment of schizophrenia?